Seelos Therapeutics Announces Updates to SLS-005 (trehalose) Programs for Europe and U.S.
22 janv. 2020 07h30 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics to Participate in 33rd Annual National MPS Society Family Conference
13 déc. 2019 08h30 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)
04 déc. 2019 08h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Reports Q3 2019 Pipeline Update
08 nov. 2019 07h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today released its third quarter pipeline update. “Seelos continued...
Seelos Therapeutics to Participate in Upcoming Investor Conference in November
18 oct. 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Jefferies 2019...
Seelos Therapeutics Announces the Addition of Scott Applebaum as Lead Strategic Regulatory Consultant
15 oct. 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today announced the addition of Scott Applebaum to its team as lead...
Seelos Therapeutics Announces Pricing of $6.7 Million Registered Direct Offering
23 août 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it has entered into a securities purchase...
Seelos Therapeutics Announces FDA Acceptance of IND Application for SLS-005 for Mucopolysaccharidosis Type III (Sanfilippo Syndrome)
22 août 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, is pleased to announce the acceptance of the Investigation New Drug...
Seelos Therapeutics to Ring Opening Bell at Nasdaq on August 12th
06 août 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that Raj Mehra, PhD, Chairman, Founder, and CEO of...
Seelos Therapeutics Announces Investigational New Drug Application Submission for SLS-005
17 juil. 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, July 17, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that it has submitted an Investigational New Drug...